Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Income from Continuing Operations (2020 - 2024)

Immuneering (IMRX) has 5 years of Income from Continuing Operations data on record, last reported at 18142915.0 in Q4 2024.

  • For Q4 2024, Income from Continuing Operations fell 16.69% year-over-year to 18142915.0; the TTM value through Dec 2024 reached 61478101.0, down 12.17%, while the annual FY2024 figure was 61478101.0, 12.17% down from the prior year.
  • Income from Continuing Operations reached 18142915.0 in Q4 2024 per IMRX's latest filing, down from 14726676.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 3606630.0 in Q2 2020 and bottomed at 18142915.0 in Q4 2024.
  • Average Income from Continuing Operations over 5 years is 11596460.17, with a median of 12879161.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: tumbled 121.47% in 2021, then decreased 0.81% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 4399079.0 in 2020, then plummeted by 149.44% to 10972870.0 in 2021, then dropped by 22.75% to 13468840.0 in 2022, then fell by 15.44% to 15547845.0 in 2023, then dropped by 16.69% to 18142915.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 18142915.0 in Q4 2024, 14726676.0 in Q3 2024, and 14087644.0 in Q2 2024.